Providers

CAR T-cell therapy results in a high incidence of cytokine release syndrome, but it is manageable in most cases.

A predictive tool considering disease duration, age at disease onset, age, and Expanded Disability Status Scale score estimated patients’ risk of transition to secondary progressive multiple sclerosis (MS).

Lumbar spine bone mineral density improved significantly and was maintained during long-term tumor necrosis factor inhibitor (TNFi) treatment for axial spondyloarthritis.

A codesigned online nutrition program could potentially fill a need for reliable and evidence-based nutrition information for patients with multiple sclerosis (MS).

Ravulizumab therapy may enable patients with paroxysmal nocturnal hemoglobinuria (PNH) to comparable achieve activity levels and patient-reported outcomes to the US general population.

This article first appeared on The Center for Biosimilars®.

This investigation was conducted among older, frail patients, a population typically underrepresented in clinical trials.

The FDA has approved axatilimab-csfr (Niktimvo) for treating adults and children with chronic graft-versus-host disease who have progressed on at least 2 prior treatments.

Caitlin Kindberg, a patient advocate from Nashville, Tennessee, discusses her experience finding proper treatment for idiopathic hypersomnia and the challenges associated with living with this condition.

Study results demonstrated significant correlations between fatigue and reductions in walking speed and mobility among patients with multiple sclerosis.

Patients with hypertension-related chronic kidney disease who increased daily fruit and vegetable consumption showed improved cardiovascular health and reduced blood pressure compared with participants who added baking soda to their diet or who received pharmacological-only treatment.

New findings from the RECOVER-Adult cohort study show that 25 routine clinical lab tests are not effective in diagnosing postacute sequelae of SARS-CoV-2 infection, echoing results from earlier studies.

The identification of unique pulmonary fibrosis endotypes is an important step in the development of precision medicine approaches for the incurable condition.

The investigational therapy for heart failure (HF) with mildly reduced or preserved injection fraction met its primary end point in the phase 3 trial, Bayer announced.

On this episode of Managed Care Cast, we're talking with the chief medical officers of CVS Health and Aetna, as well as CVS Health's chief health equity officer, about primary and preventive care engagement, the impact of telehealth, and the role of trust in patient-provider relationships.

Engaging with healthy lifestyle behaviors, including a healthy diet and physical activity, was associated with better outcomes among patients with multiple sclerosis (MS).

Accessia Health works with advocacy groups to understand specific needs, such as travel assistance, affordable care, and diagnostic testing, ensuring a personalized and human-centered approach to health equity.

New survey data reveals that more than 25% of those aged 50 years and older assume caregiver responsibilities.

The effects of the COVID-19 pandemic continue to reverberate, as shown in these new data from surveys of adults in the 50 states conducted over approximately 4 years.

The extension of the TOPAZ study provided support for the long-term benefits and safety of apitegromab therapy in patients with spinal muscular atrophy (SMA) at 36 months.

Aravindhan Veerapandiyan, MD, of the Division of Pediatric Neurology at the University of Arkansas for Medical Sciences, discussed the Duchenne muscular dystrophy (DMD) therapy landscape and barriers to treatment access.

Investigators wanted to know how well the NFlymSI-18 assessment was able to assess patient-reported outcomes in people with indolent B-cell non-Hodgkin lymphoma (NHL).